Towards Optimization of Ureteral Health and Improvement of Outcomes During Semirigid Ureteroscopy: 4.5/6 Fr vs. 6/7.5 Fr Ureteroscopes a randomized trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202102518224713

Enrollment

198

Registered

2021-02-17

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases

Interventions

4.5 Fr semirigid ureteroscopy and stone disintegration by laser

6 Ff semirigid ureteroscopy and stone disintegration by laser

control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1st episode of ureteric (middle or lower) radiopaque stones, after the failure of medical expulsive therapy,

Exclusion criteria

Exclusion criteria: We excluded patients with multiple or bilateral ureteral stones, coagulation disorders, radiolucent stones, children (age 30

Design outcomes

Primary

Measure	Time frame
incidence of ureteral mucosal injury, perforation, and hematuria	—

Secondary

Measure	Time frame
stone free rate	—

Countries

Egypt

Contacts

Public Contactmohamed Omar

Menoufia University

mohammed.kamal.omar@med.menofia.edu.eg011201066949454

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026